NMI 8739
(Synonyms: DHA-DA, NMI 8739) 目录号 : GC31111
A conjugate of DHA and dopamine
Cas No.:129024-87-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
N-Docosahexaenoyl dopamine (DHA-DA) is an amine conjugate of the neurotransmitter dopamine and the polyunsaturated fatty acid docosahexaenoic acid . DHA-DA is actively transported into the brain following intraperitoneal injections in mice, resulting in reduced general locomotor activity of 35-40% at a dose of 5 mg/kg.1 It is theorized that the DHA portion of the molecule serves as a carrier for DA through the blood-brain barrier via a DHA-mediated transport system.1 DHA-DA exhibits immune-modulating, anti-inflammatory activity in the range of 0.1-2.5 ?M, suppressing the production of nitric oxide, IL-6, CCL20, MCP-1, and PGE2 in LPS-stimulated macrophages and microglial cells without affecting NF-κB activity.2
1.Shashoua, V.E., and Hesse, G.W.N-Docosahexaenoyl, 3-hydroxytyramine: A dopaminergic compound that penetrates the blood-brain barrier and suppresses appetiteLife Sci.58(16)1347-1357(1996) 2.Wang, Y., Plastina, P., Vincken, J.-P., et al.N-docosahexaenoyl dopamine, an endocannabinoid-like conjugate of dopamine and the n-3 fatty acid docosahexaenoic acid, attenuates lipopolysaccharide-induced activation of microglia and macrophages via COX-2ACS Chem. Neurosci.Epub ahead of print(2016)
| Cas No. | 129024-87-9 | SDF | |
| 别名 | DHA-DA, NMI 8739 | ||
| Canonical SMILES | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(NCCC1=CC=C(O)C(O)=C1)=O | ||
| 分子式 | C30H41NO3 | 分子量 | 463.65 |
| 溶解度 | DMSO: ≥ 100 mg/mL (215.68 mM); Ethanol: 100 mg/mL (215.68 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1568 mL | 10.784 mL | 21.568 mL |
| 5 mM | 0.4314 mL | 2.1568 mL | 4.3136 mL |
| 10 mM | 0.2157 mL | 1.0784 mL | 2.1568 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。